ENTREP1

Summary

ENTREP1 (endosomal transmembrane epsin interactor 1, HGNC:24820) is a protein-coding gene on chromosome 9q21.12, encoding Endosomal transmembrane epsin interactor 1 (Q15884). Functions as an activator of the E3 ubiquitin protein ligase ITCH in the ubiquitination of the CXCL12-activated CXCR4 receptor.

Enables ubiquitin ligase activator activity. Involved in CXCL12-activated CXCR4 signaling pathway and negative adaptation of signaling pathway. Located in endosome membrane and plasma membrane.

Source: NCBI Gene 9413 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 140 total
• MANE Select transcript: NM_001347995

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24820
Approved symbol	ENTREP1
Name	endosomal transmembrane epsin interactor 1
Location	9q21.12
Locus type	gene with protein product
Status	Approved
Aliases	X123, ENTREP
Ensembl gene	ENSG00000135063
Ensembl biotype	protein_coding
OMIM	607710
Entrez	9413

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 7 protein_coding, 3 protein_coding_CDS_not_defined, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000257515, ENST00000303068, ENST00000377216, ENST00000455972, ENST00000460871, ENST00000469179, ENST00000643727, ENST00000645123, ENST00000645516, ENST00000911498, ENST00000956508, ENST00000956509, ENST00000956510

RefSeq mRNA: 3 — MANE Select: NM_001347995 NM_001127608, NM_001347995, NM_004816

CCDS: CCDS6629, CCDS87658

Canonical transcript exons

ENST00000303068 — 11 exons

Exon	Start	End
ENSE00001773387	69371499	69371609
ENSE00003515721	69383947	69384025
ENSE00003525288	69377611	69377744
ENSE00003567738	69388158	69388450
ENSE00003660631	69385795	69385947
ENSE00003680182	69377370	69377477
ENSE00003680915	69383630	69383759
ENSE00003691570	69375736	69375864
ENSE00003819766	69325215	69325723
ENSE00003823211	69336213	69336269
ENSE00003829037	69391601	69392456

Expression profiles

Bgee: expression breadth ubiquitous, 241 present calls, max score 97.54.

FANTOM5 (CAGE): breadth broad, TPM avg 4.9300 / max 118.1382, expressed in 742 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
96843	2.7422	680
96838	1.1003	236
96842	0.5143	266
96841	0.4151	222
96839	0.0974	57
96840	0.0608	32

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left lobe of thyroid gland	UBERON:0001120	97.54	gold quality
right lobe of thyroid gland	UBERON:0001119	97.51	gold quality
thyroid gland	UBERON:0002046	97.20	gold quality
hindlimb stylopod muscle	UBERON:0004252	94.42	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	93.83	gold quality
triceps brachii	UBERON:0001509	93.44	gold quality
secondary oocyte	CL:0000655	93.27	gold quality
gastrocnemius	UBERON:0001388	92.62	gold quality
gluteal muscle	UBERON:0002000	92.46	gold quality
muscle of leg	UBERON:0001383	92.19	gold quality
left ovary	UBERON:0002119	92.13	gold quality
skeletal muscle tissue	UBERON:0001134	91.65	gold quality
muscle organ	UBERON:0001630	91.65	gold quality
apex of heart	UBERON:0002098	91.34	gold quality
right lung	UBERON:0002167	91.16	gold quality
oocyte	CL:0000023	91.13	gold quality
deltoid	UBERON:0001476	90.67	silver quality
biceps brachii	UBERON:0001507	90.38	gold quality
right ovary	UBERON:0002118	90.36	gold quality
muscle tissue	UBERON:0002385	90.30	gold quality
vastus lateralis	UBERON:0001379	90.11	silver quality
right uterine tube	UBERON:0001302	89.67	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	89.59	gold quality
diaphragm	UBERON:0001103	89.45	silver quality
quadriceps femoris	UBERON:0001377	89.14	silver quality
tibialis anterior	UBERON:0001385	88.83	gold quality
lower esophagus muscularis layer	UBERON:0035833	88.81	gold quality
lower esophagus	UBERON:0013473	88.76	gold quality
heart left ventricle	UBERON:0002084	88.19	gold quality
cardiac ventricle	UBERON:0002082	87.91	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.56
E-HCAD-25	yes	4.44
E-GEOD-109979	no	139.75

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CTNNB1

miRNA regulators (miRDB)

33 targeting ENTREP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-7152-5P	99.60	69.33	2094
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-6727-3P	99.49	65.92	1333
HSA-MIR-19A-5P	99.36	66.93	1675
HSA-MIR-19B-1-5P	99.36	67.07	1669
HSA-MIR-19B-2-5P	99.36	67.07	1669
HSA-MIR-4722-3P	99.35	65.22	1099
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-6734-3P	99.15	66.27	1627
HSA-MIR-6738-3P	99.03	67.14	1326
HSA-MIR-922	99.02	67.23	1838
HSA-MIR-5001-3P	98.91	67.28	1394
HSA-MIR-4774-3P	98.90	67.82	737
HSA-MIR-1304-5P	98.90	68.58	1054
HSA-MIR-3074-5P	98.82	66.56	1414
HSA-MIR-2467-3P	98.65	67.18	1969
HSA-MIR-3188	98.58	65.60	878
HSA-MIR-374C-3P	98.47	67.93	451
HSA-MIR-6873-5P	98.45	66.14	1417
HSA-MIR-6804-5P	98.39	65.77	1084
HSA-MIR-4799-3P	97.78	65.97	893
HSA-MIR-4720-5P	97.46	65.67	893
HSA-MIR-5588-5P	97.46	65.70	913
HSA-MIR-4448	97.04	66.22	752

Literature-anchored findings (GeneRIF, showing 2)

• ENTREP/FAM189A2 encodes a new ITCH ubiquitin ligase activator that is downregulated in breast cancer. (PMID:34927784)
• FAM189A2 plays a tumour suppressor role in lung adenocarcinoma by influencing cell apoptosis, CXCR4 expression and tight junction proteins. (PMID:38878656)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	fam189a2	ENSDARG00000099946
mus_musculus	Entrep1	ENSMUSG00000071604
rattus_norvegicus	Entrep1	ENSRNOG00000061147

Paralogs (2): ENTREP2 (ENSG00000104059), ENTREP3 (ENSG00000160767)

Protein

Protein identifiers

Endosomal transmembrane epsin interactor 1 — Q15884 (reviewed: Q15884)

Alternative names: Endosomal transmembrane binding with epsin

All UniProt accessions (2): A0A0A0MRU1, Q15884

UniProt curated annotations — full annotation on UniProt →

Function. Functions as an activator of the E3 ubiquitin protein ligase ITCH in the ubiquitination of the CXCL12-activated CXCR4 receptor. Thereby, triggers CXCR4 endocytosis and desensitization, negatively regulating the CXCL12/CXCR4 signaling pathway.

Subunit / interactions. Interacts with ITCH; enhances the ubiquitination of CXCR4 by ITCH and the subsequent endocytosis and desensitization of the receptor. Interacts with EPN1.

Subcellular location. Early endosome membrane. Late endosome membrane. Recycling endosome membrane. Cell membrane.

Tissue specificity. Prominently expressed in muscle.

Post-translational modifications. Monoubiquitinated at Lys-274, Lys-329 and Lys-365 by ITCH.

Domain organisation. The cytoplasmic PPxY motifs mediate interaction with the WW domains of ITCH.

Similarity. Belongs to the ENTREP family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q15884-3	3, ENTREP	yes
Q15884-1	1
Q15884-4	4

RefSeq proteins (3): NP_001121080, NP_001334924, NP_004807 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR030431	ENTREP1-3	Family

UniProt features (27 total): sequence conflict 6, cross-link 3, compositionally biased region 2, splice variant 2, sequence variant 2, mutagenesis site 2, topological domain 2, region of interest 2, short sequence motif 2, signal peptide 1, chain 1, modified residue 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15884-F1	60.47	0.06

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 275, 274, 329, 365

Mutagenesis-validated functional residues (2):

Position	Phenotype
151	decreased interaction with itch and no effect on interaction with epn1; when associated with a-197.
197	decreased interaction with itch and no effect on interaction with epn1; when associated with a-151.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 137 (showing top): MORF_RAGE, MORF_FLT1, GOBP_RESPONSE_TO_PEPTIDE, GOZGIT_ESR1_TARGETS_DN, MORF_ATRX, GOBP_VESICLE_MEDIATED_TRANSPORT, MORF_ESR1, MODULE_16, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, CAIRO_HEPATOBLASTOMA_CLASSES_DN, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, MORF_PPP5C, BLALOCK_ALZHEIMERS_DISEASE_UP, MORF_FANCG, GOBP_RECEPTOR_INTERNALIZATION

GO Biological Process (3): negative adaptation of signaling pathway (GO:0022401), receptor internalization (GO:0031623), CXCL12-activated CXCR4 signaling pathway (GO:0038160)

GO Molecular Function (2): ubiquitin ligase activator activity (GO:1990757), protein binding (GO:0005515)

GO Cellular Component (6): plasma membrane (GO:0005886), early endosome membrane (GO:0031901), late endosome membrane (GO:0031902), recycling endosome membrane (GO:0055038), endosome (GO:0005768), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
endosome membrane	3
negative regulation of signal transduction	1
adaptation of signaling pathway	1
receptor-mediated endocytosis	1
chemokine (C-X-C motif) ligand 12 signaling pathway	1
C-X-C chemokine receptor CXCR4 signaling pathway	1
ubiquitin-protein transferase activator activity	1
positive regulation of ubiquitin protein ligase activity	1
binding	1
membrane	1
cell periphery	1
early endosome	1
late endosome	1
recycling endosome	1
endomembrane system	1
cytoplasmic vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

898 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ENTREP1	TJP2	Q9UDY2	851
ENTREP1	TSPO	P30536	824
ENTREP1	TMC1	Q8TDI8	761
ENTREP1	BAAT	Q14032	634
ENTREP1	APBA1	Q02410	547
ENTREP1	SOWAHA	Q2M3V2	525
ENTREP1	C2orf80	Q0P641	479
ENTREP1	ZNF497	Q6ZNH5	476
ENTREP1	BCL2L1	Q07817	470
ENTREP1	MANSC1	Q9H8J5	468
ENTREP1	DNASE2B	Q8WZ79	454
ENTREP1	RNF208	Q9H0X6	447
ENTREP1	GSK3B	P49841	436
ENTREP1	SAFB	Q15424	424
ENTREP1	BCL2	P10415	423

IntAct

74 interactions, top by confidence:

A	B	Type	Score
ENTREP1	WWP2	psi-mi:“MI:0914”(association)	0.850
ENTREP1	WWP2	psi-mi:“MI:0915”(physical association)	0.850
WWP2	ENTREP1	psi-mi:“MI:0915”(physical association)	0.850
ITCH	ENTREP1	psi-mi:“MI:0915”(physical association)	0.740
NEDD4	ENTREP1	psi-mi:“MI:0407”(direct interaction)	0.690
ENTREP1	NEDD4	psi-mi:“MI:0914”(association)	0.690
ENTREP1	WWP1	psi-mi:“MI:0915”(physical association)	0.660
ANKRD13D	ENTREP1	psi-mi:“MI:0915”(physical association)	0.660
HECW2	ENTREP1	psi-mi:“MI:0915”(physical association)	0.660
NEDD4L	ENTREP1	psi-mi:“MI:0915”(physical association)	0.660
YWHAZ	ENTREP1	psi-mi:“MI:0915”(physical association)	0.660
EPN1	ENTREP1	psi-mi:“MI:0915”(physical association)	0.580
EPN1	ENTREP1	psi-mi:“MI:0403”(colocalization)	0.580
EPN1	ENTREP1	psi-mi:“MI:2364”(proximity)	0.580
ITCH	ENTREP1	psi-mi:“MI:0915”(physical association)	0.570
ENTREP1	ITCH	psi-mi:“MI:0403”(colocalization)	0.570
ENTREP1	ITCH	psi-mi:“MI:2364”(proximity)	0.570
MYO6	ENTREP1	psi-mi:“MI:0915”(physical association)	0.550
PCNX3	ENTREP1	psi-mi:“MI:0915”(physical association)	0.550
YWHAE	ENTREP1	psi-mi:“MI:0915”(physical association)	0.550
ITCH	CXCR4	psi-mi:“MI:0914”(association)	0.540
ENTREP1	WWP2	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (178): FAM189A2 (Two-hybrid), CALCOCO2 (Two-hybrid), STAM2 (Two-hybrid), WWP1 (Two-hybrid), WWP2 (Two-hybrid), UBQLN1 (Two-hybrid), UBXN1 (Two-hybrid), TMPPE (Affinity Capture-MS), GJC1 (Affinity Capture-MS), GJA1 (Affinity Capture-MS), CHPT1 (Affinity Capture-MS), TRIM32 (Affinity Capture-MS), DNAJC1 (Affinity Capture-MS), ABCA3 (Affinity Capture-MS), SLC26A2 (Affinity Capture-MS)

ESM2 similar proteins: A0PJX4, A2A8U2, A4D2P6, A6QM06, D4A6L0, E1BBQ2, O15079, O60320, P12755, P49797, P97260, Q0D2I5, Q12770, Q15884, Q1RMB5, Q3TS39, Q3UPR0, Q4FZH1, Q5MNU5, Q5SNT2, Q5T848, Q5XKK7, Q60698, Q6A044, Q7T0Z7, Q7TMB0, Q7TPB0, Q810F0, Q86XR5, Q8BX43, Q8BXL9, Q8C419, Q8CA71, Q8K064, Q8K2Y3, Q8N114, Q8NDY8, Q8WV15, Q91WM6, Q92537

Diamond homologs: O60320, P81408, Q15884, Q4FZH1, Q5HZJ5, Q6A044

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 56 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Translesion synthesis by POLI	6	89.6×	6e-09
Regulation of innate immune responses to cytosolic DNA	5	84.6×	1e-07
InlB-mediated entry of Listeria monocytogenes into host cell	5	84.6×	1e-07
Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7	5	84.6×	1e-07
Translesion Synthesis by POLH	6	80.1×	9e-09
Translesion synthesis by REV1	5	79.3×	1e-07
Translesion synthesis by POLK	5	70.5×	2e-07
Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)	5	66.8×	2e-07

GO biological processes:

GO term	Partners	Fold	FDR
protein K63-linked ubiquitination	6	29.7×	5e-06
double-strand break repair	5	18.8×	4e-04
protein K48-linked ubiquitination	6	18.7×	7e-05
ubiquitin-dependent protein catabolic process	11	15.1×	3e-08
protein ubiquitination	17	13.0×	2e-12
proteasome-mediated ubiquitin-dependent protein catabolic process	8	7.7×	4e-04
DNA repair	6	7.1×	4e-03
DNA damage response	7	6.9×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

140 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	79
Likely benign	22
Benign	25

Top pathogenic / likely-pathogenic (0)

SpliceAI

2578 predictions. Top by Δscore:

Variant	Effect	Δscore
9:69382571:G:GT	donor_gain	1.0000
9:69383628:AGGAT:A	acceptor_gain	1.0000
9:69383629:GGATG:G	acceptor_gain	1.0000
9:69383756:GCAGG:G	donor_loss	1.0000
9:69383757:CAGG:C	donor_loss	1.0000
9:69383758:AGGT:A	donor_loss	1.0000
9:69383759:GGTAC:G	donor_loss	1.0000
9:69383760:G:GA	donor_loss	1.0000
9:69384021:TCAAG:T	donor_loss	1.0000
9:69384022:CAAGG:C	donor_loss	1.0000
9:69384023:AAGG:A	donor_loss	1.0000
9:69384025:GGTA:G	donor_loss	1.0000
9:69384026:GTA:G	donor_loss	1.0000
9:69384027:T:A	donor_loss	1.0000
9:69336266:CCTGG:C	donor_loss	0.9900
9:69336267:CTGG:C	donor_loss	0.9900
9:69336268:TGG:T	donor_loss	0.9900
9:69336269:GGTA:G	donor_loss	0.9900
9:69336270:G:GC	donor_loss	0.9900
9:69336270:G:GG	donor_gain	0.9900
9:69336271:T:A	donor_loss	0.9900
9:69371607:CTGG:C	donor_loss	0.9900
9:69371608:TGGTA:T	donor_loss	0.9900
9:69371609:GG:G	donor_loss	0.9900
9:69371610:G:A	donor_loss	0.9900
9:69371611:T:G	donor_loss	0.9900
9:69371612:AAGCA:A	donor_loss	0.9900
9:69375731:TTAA:T	acceptor_loss	0.9900
9:69375732:TAA:T	acceptor_loss	0.9900
9:69375733:AAGGT:A	acceptor_gain	0.9900

AlphaMissense

3836 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:69371550:G:A	G22R	0.999
9:69371550:G:C	G22R	0.999
9:69371551:G:A	G22E	0.999
9:69375760:T:C	C50R	0.999
9:69375762:C:G	C50W	0.999
9:69375767:G:A	C52Y	0.999
9:69375839:G:A	C76Y	0.999
9:69377418:T:C	C101R	0.999
9:69371529:T:C	C15R	0.998
9:69371545:T:C	L20P	0.998
9:69371601:T:A	C39S	0.998
9:69371601:T:C	C39R	0.998
9:69371602:G:A	C39Y	0.998
9:69371602:G:C	C39S	0.998
9:69375760:T:A	C50S	0.998
9:69375761:G:A	C50Y	0.998
9:69375761:G:C	C50S	0.998
9:69375766:T:C	C52R	0.998
9:69375768:T:G	C52W	0.998
9:69375815:T:C	L68S	0.998
9:69375838:T:C	C76R	0.998
9:69375840:T:G	C76W	0.998
9:69375860:T:C	L83P	0.998
9:69377388:T:C	C91R	0.998
9:69377401:C:A	A95D	0.998
9:69377416:T:A	V100D	0.998
9:69371543:T:A	N19K	0.997
9:69371543:T:G	N19K	0.997
9:69371603:T:G	C39W	0.997
9:69375766:T:A	C52S	0.997

dbSNP variants (sampled 300 via entrez): RS1000064870 (9:69366747 T>A), RS1000069 (9:69338730 A>G), RS1000090609 (9:69369475 T>C), RS1000129981 (9:69325926 T>C), RS1000133368 (9:69359570 C>T), RS1000197785 (9:69358080 A>G), RS1000258078 (9:69373005 CTT>C), RS1000379212 (9:69332397 T>A), RS1000381672 (9:69390275 A>C,T), RS1000395430 (9:69350188 T>C), RS1000397795 (9:69356452 G>A,T), RS1000422793 (9:69349962 A>G), RS1000475086 (9:69390601 G>A,T), RS1000499752 (9:69358060 A>G), RS1000504077 (9:69359108 G>A)

Disease associations

OMIM: gene MIM:607710 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (2): prostate cancer (MONDO:0008315), schizophrenia (MONDO:0005090)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST006281_19	Coronary artery disease in type 1 diabetes	9.000000e-06
GCST006281_20	Coronary artery disease in type 1 diabetes	9.000000e-06

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression	2
Acetaminophen	decreases expression, increases expression	2
Nickel	decreases expression	2
Oxygen	increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Silicon Dioxide	increases expression, decreases expression	2
Valproic Acid	affects expression, increases expression	2
propionaldehyde	increases expression	1
trichostatin A	decreases expression	1
sulforaphane	decreases expression	1
butyraldehyde	increases expression	1
benzo(e)pyrene	increases methylation	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
tricetin	increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Sunitinib	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Benzo(a)pyrene	affects methylation	1
Calcitriol	affects cotreatment, increases expression	1
Coumestrol	affects cotreatment, decreases expression	1
Diethylhexyl Phthalate	increases expression	1
Doxorubicin	decreases expression	1
Methapyrilene	increases methylation	1
N-Nitrosopyrrolidine	increases expression	1
Rotenone	decreases expression	1
Dihydrotestosterone	increases expression	1
Testosterone	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

600 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety